Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.45 |
| ▸ | IDO1 | P14902 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.39 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2425148 | 1.00 | TAAR1 (0.45) | TAAR1IDO1ALDH1A1AOC3SLC6A2 | |
| SCHEMBL15082795 | 1.00 | TAAR1 (0.45) | TAAR1IDO1ALDH1A1AOC3SLC6A2 | |
| SCHEMBL5988255 | 0.84 | GABRA1 (0.46) | TAAR1ALDH1A1SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL27565475 | 0.83 | GABRA1 (0.41) | ALDH1A1GABRA1GABRB2 | |
| SCHEMBL5680506 | 0.83 | TAAR1 (0.42) | TAAR1IDO1ALDH1A1AOC3SLC6A2 | |
| SCHEMBL139640 | 0.82 | GABRA1 (0.52) | TAAR1IDO1ALDH1A1AOC3SLC6A2 | |
| SCHEMBL18901781 | 0.82 | TAAR1 (0.48) | TAAR1IDO1ALDH1A1AOC3SLC6A2 | |
| SCHEMBL5681973 | 0.81 | TAAR1 (0.43) | TAAR1IDO1ALDH1A1AOC3SLC6A2 | |
| SCHEMBL6200987 | 0.80 | TAAR1 (0.46) | TAAR1IDO1ALDH1A1AOC3SLC6A2 | |
| SCHEMBL10586668 | 0.79 | TAAR1 (0.52) | TAAR1IDO1ALDH1A1AOC3SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2834233-B1 | NEW ALPHA2 ADRENOCEPTOR AGONISTS | ORION CORP (FI) | 2018-04-25 | — | — | EP | disclosed |
| CN-104220437-B | The adrenoceptor agonists of α 2 | 奥赖恩公司 | 2017-11-10 | — | — | CN | disclosed |
| US-9249147-B2 | Tyrosine kinase inhibitors | CHEMBRIDGE CORPORATION (US) | 2016-02-02 | — | — | US | disclosed |
| US-9249127-B2 | Alpha2 adrenoceptor agonists | ORION CORPORATION (FI) | 2016-02-02 | — | — | US | disclosed |
| EP-2966076-A1 | NOVEL TYROSINE KINASE INHIBITORS | ChemBridge Corporation (US) | 2016-01-13 | — | — | EP | disclosed |
| CN-102036990-B | Novel tyrosine kinase inhibitors | CHEMBRIDGE CORP. (US) | 2015-09-30 | — | — | CN | disclosed |
| EP-2262807-B1 | NOVEL TYROSINE KINASE INHIBITORS | CHEMBRIDGE CORP (US) | 2015-08-12 | — | — | EP | disclosed |
| US-20150065550-A1 | NEW ALPHA2 ADRENOCEPTOR AGONISTS | ORION CORPORATION (FI) | 2015-03-05 | — | — | US | disclosed |
| US-20150011539-A1 | NOVEL TYROSINE KINASE INHIBITORS | CHEMBRIDGE COPRPORATION | 2015-01-08 | — | — | US | disclosed |
| CN-104220437-A | New alpha2 adrenoceptor agonists | ORION CORP | 2014-12-17 | — | — | CN | disclosed |
| US-8815906-B2 | Tyrosine kinase inhibitors | CHEMBRIDGE CORPORATION (US) | 2014-08-26 | — | — | US | disclosed |
| US-8815906-B2 | Tyrosine kinase inhibitors | CHEMBRIDGE CORPORATION (US) | 2014-08-26 | — | — | US | disclosed |
| US-8815906-B2 | Tyrosine kinase inhibitors | CHEMBRIDGE CORPORATION (US) | 2014-08-26 | — | — | US | disclosed |
| US-20130053376-A1 | NOVEL TYROSINE KINASE INHIBITORS | CHEMBRIDGE COPRPORATION | 2013-02-28 | — | — | US | disclosed |
| CN-102036990-A | Novel tyrosine kinase inhibitors | CHEMBRIDGE CORP | 2011-04-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150065550-A1 | NEW ALPHA2 ADRENOCEPTOR AGONISTS | ADRA2A, ADRB2, ADRA2C | TAAR1 75/4885IDO1 2450/4885ALDH1A1 465/4885 |
| US-20150011539-A1 | NOVEL TYROSINE KINASE INHIBITORS | ABL1, RET, TTBK1 | TAAR1 1120/4885IDO1 1656/4885ALDH1A1 2215/4885 |
| US-20130053376-A1 | NOVEL TYROSINE KINASE INHIBITORS | ABL1, RET, TTBK1 | TAAR1 1120/4885IDO1 1656/4885ALDH1A1 2215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.